Treatment outcomes of micropulse transscleral cyclophotocoagulation in advanced XXXX .

@entity1939 @entity1 @entity726
UNASSIGNED: @entity726 is the leading cause of irreversible @entity1939 worldwide. The goal of this study was to describe our experience with the novel micropulse transscleral cyclophotocoagulation (MP-TSCPC; IRIDEX IQ810 Laser Systems, CA) in @entity1 with advanced @entity726 . @entity1 with advanced @entity726 who underwent MP-TSCPC were included in our study. Laser settings were 2000  mW of 810  nm infrared diode laser set on micropulse delivery mode. The laser was delivered over 360   for 100-240  s. The duty cycle was 31.3  %, which translated to 0.5  ms of "on time" and 1.1  ms of "off time." Surgical success was defined as an intraocular pressure (IOP) of 6-21  mmHg or a reduction of IOP by 20  % at the last follow-up visit. Failure was defined as an inability to meet the criteria for success or a need for incisional @entity726 surgery. Nineteen @entity1 underwent MP-TSCPC with mean follow-up of 60.3  days. Mean IOP dropped from 37.9  mmHg preoperatively to 22.7  mmHg at last follow-up, representing a 40.1  % decrease. The success rate for initial treatment was 73.7  % (n   =   14). Three @entity1 underwent a second treatment, increasing the overall success rate to 89.5  % (n   =   17). Four @entity1 gained one line of vision, and four @entity1 lost one line of vision. The novel MP-TSCPC laser had a high rate of surgical success after a short follow-up period in @entity1 with advanced @entity726 . Further long-term evaluation and comparison to the traditional transscleral cyclophotocoagulation are warranted.
